This invention reports pharmacoperones for their novel use of therapeutics in the treatment of nephrogenic diabetes insipidus (NDI). Pharmacoperones are small molecules that enter the cell and serve as a scaffolding to allow mutated proteins to route correctly. In NDI, there is a mutation in the V2 receptor protein. Here, the inventor has reported over 140 pharmacoperones to the V2 receptor; therefore, the pharmacoperones may act as drugs specifically against the known pathology of NDI.
Reference Number: D-1209
Features, Benefits & Advantages:
Non-antagonist pharmacoperones for nephrogenic diabetes insipidus treatment
Intellectual Property: A Provisional Application was filed in October of 2015 and converted to a PCT application in October of 2016.
Development Stage: This technology is still being tested; however, the compounds have been identified and experimentally confirmed. Animal, pre-clinical, and clinical studies are in the near future.
Michael Conn, Ph.D., Sr. Vice President for Research, Associate Provost and Professor of Internal Medicine and Cell Biology, Texas Tech University Health Sciences Center, Lubbock, Texas.
Keywords: pharmacoperone, nephrogenic diabetes insipidus, mutant, V2 receptor